Wilmer Cutler Pickering Hale and Dorr is representing Verde Bioresins, Inc. in the transaction, and Snell & Wilmer is representing Nxu Inc. Verde Bioresins, Inc., a...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr and Cooley advised on Terns Pharmaceuticals, Inc. on the offering, and Davis Polk & Wardwell advised the underwriters. Terns Pharmaceuticals,...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (Kymera), a clinical-stage biopharmaceutical company, announced its public offering of 2,830,533 shares...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Karyopharm Therapeutics Inc. on the transactions. Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Wonder Group in the transaction, and Wilmer Cutler Pickering Hale and Dorr represented Blue Apron Holdings. Wonder Group (“Wonder”) announced that it has...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Omeat Inc. in the transaction. Omeat Inc. announced it has secured $40 million in funding as it emerges from stealth...
You must be a Standard 1 Year member to access this content.
WilmerHale represented Blue Apron in the transaction. Blue Apron (NYSE: APRN), an American ingredient-and-recipe meal kit company, announced the signing and closing of a transaction with...
You must be a Standard 1 Year member to access this content.
